Real-world experience of lenvatinib-based therapy in patients with advanced hepatocellular carcinoma
In our study cohort, there were no statistically significant differences observed in the survival rates between patients treated with lenvatinib monotherapy and those treated with a combination of lenvatinib and immunotherapy. The incorporation of ALBI grade and NLR facilitates the stratification of survival outcomes in patients with unresectable HCC undergoing lenvatinib monotherapy.
Authors
- Guan‐Tarn Huang (ORCID: https://orcid.org/0000-0001-7004-826X)
- Wen‐Pang Su
- Hung‐Yao Chen (ORCID: https://orcid.org/0000-0003-1085-7166)
- Hung‐Wei Wang (ORCID: https://orcid.org/0000-0001-6574-1561)
- Cheng‐Yuan Peng (ORCID: https://orcid.org/0000-0001-9030-6086)
- Jung‐Ta Kao (ORCID: https://orcid.org/0000-0002-3801-5342)
- Wei‐Fan Hsu (ORCID: https://orcid.org/0000-0002-0738-417X)
- Che-Wei Chang (ORCID: https://orcid.org/0000-0002-5864-017X)
- Hsueh‐Chou Lai (ORCID: https://orcid.org/0000-0002-0126-6447)
Institutions
- China Medical University (TW)
- China Medical University Hospital (TW)
Publication Details
- Journal
- Journal of Gastrointestinal Oncology
- Published
- 2024-10-01
- DOI
- https://doi.org/10.21037/jgo-24-351
- Citations
- 1
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.37
Funders
- China Medical University Hospital
- China Medical University
- Division of Materials Research